In late April 2020, we highlighted opportunity in Fiverr (FVRR).
At the time, it traded at just $36.19. It’s now up to $47 in just weeks after posting revenue growth of 44% with accelerating growth.
Ofer Katz, Fiverr CFO, added, “We are very happy with Q1 results with strong topline growth, strong gross margin and significant improvement in EBITDA. Built on these achievements, the visibility inherent to our business model, and the tailwind we experienced in recent weeks, we are providing strong guidance for the second quarter of 2020 and revised our full year outlook upward from prior guidance.”
Congratulations on the win if you bought the stock.
As for newer opportunities, take a look at TG Therapeutics (TGTX). The company just reported positive topline results from the global UNITY-CLL Phase 3 trial evaluating the combination of umbralisib plus ublituximab (U2) compared to obinutuzumab plus chlorambucil in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL).
Even after rising from $11 to $18.64 in recent days, there’s still plenty of upside potential here, in our opinion.